Geron Corp. buy melinda
Start price
03.09.12
/
50%
€2.25
Target price
04.03.13
€2.80
Performance (%)
-51.11%
End price
04.03.13
€1.10
Summary
This prediction ended on 04.03.13 with a price of €1.10. The BUY prediction by melinda for Geron Corp. performed very badly with a performance of -51.11%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Geron Corp. | 1.025% | 1.025% | 50.625% | 317.517% |
iShares Core DAX® | -0.598% | 0.645% | 10.813% | 15.396% |
iShares Nasdaq 100 | -3.290% | -4.193% | 23.772% | 40.773% |
iShares Nikkei 225® | -0.796% | -0.582% | 8.390% | 8.288% |
iShares S&P 500 | -1.164% | -0.857% | 23.003% | 41.152% |
Comments by melinda for this prediction
In the thread Geron Corp. diskutieren
pharma
Geron Corp ist ein biopharmazeutisches Unternehmen, das therapeutische Klasse für Krebs entwickelt (Brust, Lunge)
(Laufzeit überschritten)